An interventional study of Cochlear implant and Dexamethasone in Hearing Loss, sponsored by Cochlear. Active, not recruiting at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Cochlear · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Hearing Loss by Cochlear — 5 open to participants now, 12 under way, none of them phase 3. Hearing Loss · Cochlear.
Among the 50 studies in Hearing Loss by Cochlear, this one is the 7th largest by enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2025, is one of 43 with no phase, reaches primary completion later than 0 of the 11 other live ones, and was the 41st registered.
796 studies on the registry are indexed under Hearing Loss; 194 are open to participants now.
Browse Hearing Loss studies →5 of the 50 studies in Hearing Loss by Cochlear are open now, in 6 countries. Recruiting first, the newest first:
Cochlear · Sites in Belgium, Spain
Ages 18+
Cochlear · Sites in Belgium, Netherlands
Ages 18+
Cochlear · Sites in Australia
Ages 18+
Cochlear · Sites in Germany
Ages 18+
Cochlear · Sites in United States, Australia
Ages 18+
By country, each count listing its studies:
Of the 124 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 42 (34%) stop at 75 or younger; 46 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is above the median of 44 across 561 interventional studies indexed under Hearing Loss.
Median enrollment 32 across the 43 interventional studies, 153 across the 7 observational. Of the 37 that completed or were terminated, 27 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cochlear is the lead sponsor of 92 studies on the registry; 9 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
6 of the studies in Hearing Loss by Cochlear that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07139327CochlearA Pivotal Study to Evaluate the Efficacy and Safety of a Totally Implantable Cochlear Implant (TICI) System in Adults | 2027-04 |
| NCT06098482CochlearAn Investigation to Validate Speech Perception Assessment for Adult Cochlear Recipients Using a Mobile Research App | 2027-05-02 |
| NCT06805175CochlearA Study to Evaluate the Safety and Performance of a Vestibular Implant in Adults to Provide Balance Restoration | 2027-06 |
| NCT06641999CochlearEvaluating How a Tinnitus Implant Affects Tinnitus Loudness in Adults With Chronic Tinnitus and Varying Levels of Hearing Loss | 2027-07 |
| NCT07287124CochlearA Pivotal Study to Evaluate the Clinical Benefit, Performance and Safety of a Totally Implantable Cochlear Implant (TICI) System in Adults | 2027-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies in Hearing Loss by Cochlear, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical study will test a new type of cochlear implant known as CI632D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation and reduce tissue injury, which is common after any type of surgery. The goal is to learn if the dexamethasone in the CI632D implant lessens these reactions inside the ear following surgery and if this makes the implant work as well, or even better, in improving hearing than what would be expected with a standard cochlear implant. The study will be conducted in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve (the nerve that carries sound signals from the ear to the brain). The study participants will receive the CI632D experimental implant and will complete tests to see how well they are hearing and how well the implant is working.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be implanted with the slim modiolar dexamethasone-eluting electrode array.
Device: Cochlear implant · Drug: Dexamethasone
CI632D cochlear implant
Also known as: CI632D, Slim modiolar dexamethasone-eluting electrode array
CI632D, dexamethasone-eluting cochlear implant
Also known as: CI632D, Slim modiolar dexamethasone-eluting electrode array
Coprimary endpoint 1: Mean monopolar 1 plus 2 (MP1+2) impedances (kOhms) at 3 months postactivation
Impedance will be measured across the active electrodes of the implant for each participant.
Time frame: On day of implantation and at 1- and 3-months postactivation
Coprimary endpoint 2: Mean change in word recognition score in the best unilateral listening mode in quiet from preimplantation to 3 months postactivation
Within-subject change in consonant-nucleus-consonant (CNC) words in quiet (% correct) calculated as the average across 2 runs of the test conducted on each participant. CNC word score ranges from 0-100%, higher the score the better the outcome.
Time frame: Preoperative baseline and 3-months postactivation
Mean within-subject change in the global score of the Speech, Spatial, and Qualities of hearing scale (SSQ12) from preimplantation to postimplantation
Within-subject change in Global SSQ12 scores at 6-months postactivation compared with preoperative baseline. The global SSQ12 score ranges from 0-10, higher the score the better the outcome.
Time frame: Preoperative baseline and 6-months postactivation
Mean within-subject change in sentence recognition score in the best unilateral listening mode in noise from preimplantation to postimplantation
Within-subject change in AzBio sentence in noise score at a +10 dB Signal-to-Noise Ratio (SNR) at 6-months postactivation compared with preoperative baseline. AzBio score ranges from 0-100%, higher the score the better the outcome.
Time frame: Preoperative baseline and 6-months postactivation
Mean within-subject change in sentence recognition score in the best bilateral listening mode in noise from preimplantation to postimplantation
Within-subject change in AzBio sentence in noise score at a +10 dB Signal-to-Noise Ratio (SNR) at 6-months postactivation compared with preoperative baseline. AzBio score ranges from 0-100%, higher the score the better the outcome.
Time frame: Preoperative baseline and 6-months postactivation
Proportion of participants who experience an adverse event and the proportion of participants who experience a device deficiency throughout the study
Adverse events will be recorded as overall, by severity, by relatedness to device or procedure, or by seriousness. Device deficiency will be recorded as overall and by type.
Time frame: From implantation to 12-months postimplantation (study end)
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Feb 2026, 12 months.
Of 126 industry-sponsored interventional studies with no phase under Hearing Loss, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's 12 months is above that.
Counting every sponsor, half of 323 studies reached it within 19 months; a quarter within 5 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone